Published: 18 September 2022
Author(s): Marta Sagastagoitia-Fornie, Eduardo Barge-Caballero, Gonzalo Barge-Caballero, David Couto-Mallón, María J. Paniagua-Martín, Daniel Enríquez-Vázquez, Paula Blanco-Canosa, Zulaika Grille-Cancela, Manuel Jiménez-Navarro, Javier Muñiz, José M. Vázquez-Rodríguez, María G. Crespo-Leiro
Section: Original article

Heart Failure (HF) and cancer are the main causes of morbidity and mortality in developed countries [1], and their prevalence is increasing due to ageing of the population. Therefore, patients with both pathologies represent a challenge in our daily clinical practice [2]. Several cancer therapies have cardio-toxic effects and may increase de risk of developing HF in patients with malignancies [3]. Furthermore, a few recent studies have suggested that there could also be a relation between HF and cancer in the opposite direction, in other words, that patients with HF might be exposed to an increased risk of incident malignancies [4–9].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.